TP53 and acute myeloid leukemia: Several studies have demonstrated that there are no differences in terms of OS and EFS between AML patients with missense TP53 mutations and those with truncating aberrations and that GOF activities elated for some missense TP53 variants do not represent the crucial mechanism of treatment resistance (66–69).